POTS and Ehlers-Danlos Syndrome Overlap

POTS and Ehlers-Danlos Syndrome show up together far more often than chance would allow, and the reason comes down to shared plumbing: connective tissue that doesn't hold its shape the way it should. EDS is a group of 13 heritable disorders involving joint hypermobility, skin fragility, and tissue laxity, with hEDS (the hypermobile type) making up 80 to 90% of cases. POTS is a form of orthostatic intolerance marked by a heart rate jump of 30 beats per minute or more on standing, without the blood pressure drop seen in fainting disorders. Both skew young and female, and that overlap in who gets sick points toward a shared cause, not two unrelated diseases coincidentally landing on the same people.

How connective tissue dysfunction plausibly drives both conditions at once

Start with the vessels. In EDS, collagen defects mean vein walls stretch further than they should when a person stands up. Blood pools in the legs and belly instead of returning to the heart, stroke volume drops, and the heart compensates by beating faster. That's the POTS pattern, and it's the most direct line between the two diagnoses: a structural vessel problem produces a measurable heart rate problem.

Vessel laxity is only one piece, though. Small fiber neuropathy is another. The unmyelinated nerve fibers that carry pain signals, called A-delta and C-fibers, also handle sweating, skin blood flow, and vasoconstriction. Damage one function and the other usually follows. This kind of nerve fiber loss shows up in hEDS family members who also have dysautonomia, which suggests the nerve damage and the joint laxity aren't separate problems that happen to land in the same person.

Then there's fascia, the connective tissue scaffold wrapped around muscles and organs that also houses dense networks of autonomic nerves. In hEDS and hypermobility spectrum disorder (HSD), fascia consistently shows abnormal thickness, poor gliding, and stiffness. Fascia does double duty, holding tissue together and feeding sensory information back to the brain, so dysfunction here hits both proprioception (sense of body position) and autonomic regulation at once.

Baroreflex sensitivity, the feedback loop that stabilizes blood pressure when someone changes position, is measurably different in hEDS and HSD patients who have POTS compared to those who don't. That may explain why some hypermobile people develop orthostatic tachycardia and others don't, even with similar joint symptoms.

A subset of patients also show a hyperadrenergic pattern: an exaggerated surge of norepinephrine on standing. Viral illness and immune triggers, including SARS-CoV-2, seem able to set off dysautonomia in people who were already genetically primed for it, which is part of why POTS recognition spiked during the Long COVID years.

None of these five mechanisms, vascular laxity, small fiber neuropathy, fascial dysfunction, altered baroreflex response, and hyperadrenergic or immune triggers, works alone. They tend to stack in the same patient at the same time, which is why POTS-plus-EDS presentations look so different from one person to the next. Deconditioning matters here too, but not the way it does in POTS alone. In isolated POTS, deconditioning is often the main driver behind the symptoms. In POTS-plus-EDS, deconditioning piles onto connective tissue and nerve problems that came first. Treating it as the root cause in that second group means mistaking a symptom for the disease, and that mistake is common enough to deserve stating clearly.

How often the two conditions actually co-occur, and what the numbers leave unresolved

The overlap is common. How common depends entirely on who's counting. A systematic review in Autonomic Neuroscience (Kwok et al., 2026), pulling from MEDLINE and EMBASE through December 2025 across 30 studies covering 8,421 EDS patients and 12,983 POTS patients, found POTS rates in EDS patients ranging from 17.5% to 92.7%. Going the other direction, EDS rates in POTS patients ranged from 17.9% to 50.0%. That's nearly the entire spectrum, and it tells you the number itself isn't the finding.

The spread is the finding. Specialist clinics, where clinicians already know what hEDS looks like on exam, report far higher co-occurrence than community or database samples, where most doctors have never been trained to spot it. Smaller, targeted studies back this up. Choudhary et al. (2025) found 39.5% of hEDS or HSD patients had comorbid POTS. Daylor et al. (2025), a large international study of 3,906 people with EDS or HSD, found 52.7% had POTS, with EDS patients carrying twice the POTS risk of HSD patients. At Cleveland Clinic, an evaluation of 322 adults with POTS found one in five had EDS, and among those, 49.0% had POTS. Miller et al. (2020), looking at 91 POTS patients, found 31% met full hEDS criteria, with another 24% showing generalized joint hypermobility without meeting every criterion.

hEDS has no genetic test, so every number above depends on whether the clinician running that particular study knew to check for joint hypermobility in the first place. That knowledge is unevenly distributed across specialties and regions, so treat every co-occurrence figure here as a floor, not a ceiling.

What holds steady across the noise, though, is the burden. Across the Kwok et al. (2026) review, patients with both conditions used more medication, including more pain medication, saw doctors more often, and reported more gastrointestinal symptoms than people with POTS alone. The rate of overlap is genuinely uncertain. The weight of carrying both conditions at once is not, and that's the number that should guide how a clinic actually treats these patients.

hEDS, POTS, and mast cell activation syndrome (MCAS) increasingly get grouped as a triad, and treating them as three unrelated coincidences is the mistake to avoid here. They're separate diagnoses on paper, but they emerge from overlapping breakdowns in connective tissue integrity, autonomic control, and mast cell behavior. A clinician who screens for only one is missing the other two by default, not by bad luck.

GI symptoms show the convergence clearly. POTS patients commonly report visceral hypersensitivity and dysmotility. MCAS causes nausea and vomiting in more than half of patients who have it. In a survey of 603 people with HSD or hEDS, 98% met criteria for at least one functional GI disorder, compared to 47% of controls, with the bowel affected in 90% of cases versus 40% in controls. That gap, 98% against 47%, is the whole argument for treating this as one cluster instead of four separate referrals.

There's a neurological angle too. In POTS, autonomic dysregulation affects neurotransmitter signaling in ways that can influence mood directly, not just as a side effect of feeling sick. That creates a feedback loop with the psychological toll documented separately in EDS and HSD populations, which the mental health section below picks back up.

Patients living with symptoms across the gut, the brain, energy levels, and autonomic function aren't juggling four separate mysteries stacked by bad luck. They likely share one root. For clinicians, that argues for working up the whole cluster at the first visit rather than chasing each complaint separately as it walks through the door, one referral at a time, over several years.

Why diagnosis takes so long and what sustains the delay

The delays here are long enough to cause real harm on their own, and the harm is the point, not a footnote to it. POTS takes an average of 8 to 10 years to diagnose. EDS averages 14 years, and up to 20 years for hEDS or HSD specifically, according to POTS UK. Add a psychiatric comorbidity to the mix, and the average EDS diagnostic delay stretches to 22 years.

Several structural problems keep that delay in place, and none of them are mysterious. hEDS has no genetic marker, so diagnosis rests entirely on a clinician's familiarity with clinical criteria like the Beighton score, and that familiarity varies wildly by region and specialty. Both POTS and EDS also get routinely misdiagnosed as anxiety, because palpitations, fatigue, GI complaints, and widespread pain overlap heavily with psychiatric presentations on paper. Add a general shortage of specialists and no agreed diagnostic pathway, and delay stops being the exception. It becomes the default outcome, without softening.

The cost is not abstract paperwork friction. The hEDS START report (Berg and Dockrill, 2024), surveying a Scottish population, found an 87% chronic pain rate, a number that reflects years of pain going unmanaged while a diagnosis sat out of reach. A Swedish study cited in that same report found earlier EDS diagnosis had a protective effect on later mental health outcomes. Delayed diagnosis here carries a body count, not just a wait time.

The co-occurrence compounds all of it. A patient diagnosed with POTS first might wait years before anyone thinks to check for EDS, and the reverse happens just as often. Each condition can mask the other, or absorb blame for symptoms that actually belong to its counterpart.

The mental health toll that accumulates alongside the physical burden

The psychological burden in this population is heavy, and routine care still misses most of it. A 2025 cross-sectional study of 59 HSD or hEDS patients in Calgary found 53% met criteria for major depressive disorder. A larger retrospective review of 1,035 patients assessed at the GoodHope EDS Clinic in Toronto found 53 to 87% reported current or past anxiety or depressive symptoms, with meaningful minorities reporting PTSD (4.7 to 34.8%), disordered eating (19%), self-harm (3 to 29.2%), and suicidal behavior (7.8 to 18.6%). Those ranges are wide, but even the low end of each one describes a population in real distress, not a handful of edge cases.

Some of this has a biological root, not just a situational one. POTS involves dysregulation of norepinephrine and related autonomic signaling, so mood symptoms in this population likely stem partly from the dysautonomia itself, not purely from the stress of being chronically ill. That distinction matters clinically: treating mood symptoms as free-floating anxiety, disconnected from the autonomic dysfunction driving them, means treating the wrong target.

Misdiagnosis compounds the damage on top of that. Patients frequently get told their symptoms are anxiety before anyone considers the physical explanation, and that sequence erodes trust, both in the medical system and in their own read of their bodies. Years of diagnostic delay and symptom dismissal are isolating on their own terms, and the mental health numbers above likely reflect that isolation as much as any neurochemical process running underneath it.

Managing all of this day to day carries its own cognitive weight, too. Tracking pain, fatigue, GI symptoms, autonomic instability, and mood across several overlapping conditions is a real workload, one that calls for structured support between appointments rather than more visits stacked onto an already long specialist list.

What the 2026 EDS reclassification means for patients currently navigating both diagnoses

hEDS stands alone among the 13 EDS types in having no known causative gene. Every other type has an identified gene and can, in principle, be confirmed through genetic testing, though even that testing doesn't always turn up a clear variant. That single fact explains most of what makes hEDS diagnosis slow: it's a clinical call, it depends on the person examining you knowing what to look for, and there's no lab result to fall back on when the exam findings are ambiguous.

The Ehlers-Danlos Society's Road to 2026 initiative set out to change that, in part through the HEDGE study, which sequenced more than 1,000 hEDS patients at the Broad Institute. The early findings cut two ways. Original clinical diagnoses turned out correct in over 99% of participants, which validates what patients and their doctors had been observing all along without a test to back it up. But no single causative gene turned up. Instead, the condition looks like it involves multiple rare genetic variants interacting in complex ways, not one clean mutation waiting to be found.

The updated classification framework covering all EDS types and HSD is set for publication on December 2, 2026, in the American Journal of Medical Genetics, with additional hEDS and HSD-specific diagnostic and management guidance expected in March 2027. Part of the ongoing work involves refining how HSD and hEDS are classified, a process that would directly affect how patients get categorized and, by extension, how their POTS gets understood and treated. The initiative is also building interactive digital diagnostic tools meant to help clinicians who aren't EDS specialists recognize it faster than the current average allows.

For patients currently sitting with an HSD diagnosis, or no diagnosis at all, the 2026 and 2027 framework may bring real clarity to where they fit. For those already diagnosed with hEDS, the absence of a single gene shouldn't read as bad news. If anything, it confirms the complexity patients have been describing all along matches what they experienced.

How to communicate the combined symptom burden more effectively to clinicians

Patients with both POTS and EDS live with symptoms scattered across autonomic, musculoskeletal, GI, neurological, and psychiatric systems, and rarely does one clinician see the full picture at once. Combine that with the finding from Kwok et al. (2026) that this group uses more medication and sees more providers than people with POTS alone, and the predictable result is information split across multiple charts that never talk to each other.

Bringing a clear, chronological symptom history into an appointment changes what a clinician can actually see. Instead of a list of disconnected complaints, a doctor sees a pattern, and a pattern is much harder to wave off as anxiety before anyone's looked at the connective tissue angle underneath it. A one-page timeline beats a folder of separate specialist notes every time, because it forces the connections onto the page instead of leaving them to be inferred.

Two things are worth tracking closely and bringing to every single visit, not just the first one:

• Orthostatic symptoms: when they hit, how long they last, what sets them off or eases them, and whether they're worse after eating or after exercise.
• GI symptoms: timing relative to meals, specific triggers, and how they relate to the orthostatic and energy patterns above rather than standing alone as an unrelated complaint.

Laid out this way, a symptom log stops reading like a scattered list of complaints and starts reading like the connected picture it actually is. That shift, from fragments to pattern, is often what moves a diagnosis from years away to something a clinician can act on the same afternoon.